SCHEMBL22372185

SCHEMBL22372185

O=C(NCC1CC1)c1ncc[nH]1

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.49
HTR6 P50406 1/20 0.43
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
CNR1 P21554 1/20 0.39
HTR4 Q13639 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1668641 0.88 MAPK14 (0.44) MAPK14HTR6CNR1HTR4TDP1
SCHEMBL5375153 0.76 GRIN2B (0.63)
SCHEMBL3810267 0.76 PRMT5 (0.41) HTR6PRMT5WDR77
SCHEMBL2428932 0.76 NPC1 (0.45) PRMT5WDR77
SCHEMBL8872434 0.75 EGLN1 (0.47) PRMT5WDR77EGLN1
SCHEMBL2962867 0.75 SMYD3 (0.49)
SCHEMBL26529206 0.75 NEK1 (0.46) HTR6PRMT5WDR77CNR1
SCHEMBL2423193 0.75 NPC1 (0.40) MAPK14
SCHEMBL22372152 0.74 L3MBTL1 (0.56) TDP1
SCHEMBL2876897 0.73 SMN1; SMN2 (0.51) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264138-B2 Process for the preparation of microbiocidal oxadiazole derivatives SYNGENTA CROP PROTECTION AG (CH) 2025-04-01 US disclosed
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2022-06-23 US disclosed
US-11358957-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2022-06-14 US disclosed
US-20200277287-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2020-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264138-B2 Process for the preparation of microbiocidal oxadiazole derivatives CYP51A1, MPO, NOX5 MAPK14 2218/4885HTR6 4402/4885PRMT5 1418/4885
US-20200277287-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES PRF1, NOX1, ARG2 MAPK14 3579/4885HTR6 3828/4885PRMT5 1387/4885
US-11358957-B2 Microbiocidal oxadiazole derivatives PRF1, NOX1, ARG2 MAPK14 3579/4885HTR6 3828/4885PRMT5 1387/4885
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES CYP51A1, MPO, NOX5 MAPK14 2218/4885HTR6 4402/4885PRMT5 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.